AMG 719

Drug Profile

AMG 719

Latest Information Update: 21 Dec 2007

Price : $50

At a glance

  • Originator Amgen
  • Class Antirheumatics
  • Mechanism of Action Interleukin 1 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No

Highest Development Phases

  • Discontinued Rheumatoid arthritis

Most Recent Events

  • 17 Nov 2003 Data presented at the 67th Annual Scientific Meeting of the American College of Rheumatology and the 38th Annual Meeting Association of Rheumatology Health Professionals (ACR/ARHP-2003) have been added to the Rheumatic Disease pharmacodynamics section
  • 31 Oct 2002 Phase-II clinical trials in Rheumatoid arthritis in USA (SC)
  • 05 Jul 2002 Phase-I clinical trials in Rheumatoid arthritis in USA (SC)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top